ATE406449T1 - Antigene und vektoren für impfung - Google Patents

Antigene und vektoren für impfung

Info

Publication number
ATE406449T1
ATE406449T1 AT02751532T AT02751532T ATE406449T1 AT E406449 T1 ATE406449 T1 AT E406449T1 AT 02751532 T AT02751532 T AT 02751532T AT 02751532 T AT02751532 T AT 02751532T AT E406449 T1 ATE406449 T1 AT E406449T1
Authority
AT
Austria
Prior art keywords
fusion protein
vaccination
antigens
vectors
domain
Prior art date
Application number
AT02751532T
Other languages
English (en)
Inventor
Nicholas Valiante
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE406449T1 publication Critical patent/ATE406449T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT02751532T 2001-06-06 2002-05-30 Antigene und vektoren für impfung ATE406449T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0113798.3A GB0113798D0 (en) 2001-06-06 2001-06-06 Antigens and vectors for vaccination

Publications (1)

Publication Number Publication Date
ATE406449T1 true ATE406449T1 (de) 2008-09-15

Family

ID=9916045

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02751532T ATE406449T1 (de) 2001-06-06 2002-05-30 Antigene und vektoren für impfung

Country Status (6)

Country Link
US (2) US7541180B2 (de)
EP (1) EP1440156B1 (de)
AT (1) ATE406449T1 (de)
DE (1) DE60228603D1 (de)
GB (1) GB0113798D0 (de)
WO (1) WO2002098456A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005017163A2 (en) * 2003-08-15 2005-02-24 Imperial College Innovations Limited Phenotypic knockout of cell-surface proteins
AU2006311586A1 (en) * 2005-11-08 2007-05-18 Avi Biopharma, Inc. Immunosuppression compound and treatment method
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
AU2013202533B2 (en) * 2005-11-08 2015-11-12 Sarepta Therapeutics, Inc. Immunosuppression Compound and Treatment Method
WO2008056623A1 (en) * 2006-11-09 2008-05-15 Daiichi Sankyo Company, Limited Composition for introduction of nucleic acid
CN108129554A (zh) 2010-08-10 2018-06-08 洛桑聚合联合学院 红细胞结合性治疗剂
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9962436B2 (en) 2012-07-26 2018-05-08 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Multimeric fusion protein vaccine and immunotherapeutic
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
SG10202010936RA (en) 2014-02-21 2020-12-30 Ecole Polytecnique Fed De Lausanne Epfl Epfl Tto Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
WO2016073433A1 (en) 2014-11-06 2016-05-12 E. I. Du Pont De Nemours And Company Peptide-mediated delivery of rna-guided endonuclease into cells
EP3115039B1 (de) * 2015-07-09 2021-12-15 beniag GmbH Verfahren zum herstellen einer fusionsmischung zur übertragung eines geladenen moleküls in und/oder durch eine lipidmembran
WO2017060857A1 (en) 2015-10-08 2017-04-13 The Governors Of The University Of Alberta Hepatitis c virus e1/e2 heterodimers and methods of producing same
EP3638296A1 (de) 2017-06-16 2020-04-22 The University Of Chicago Zusammensetzungen und verfahren zur herbeiführung einer immuntoleranz
CN112384239A (zh) 2018-05-09 2021-02-19 芝加哥大学 影响免疫耐受的组合物和方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ500151A (en) * 1997-03-27 2001-01-26 Univ Melbourne A general method for attaching DNA molecule comprising non-antibody target molecule (eg. CTLA-4 or L-selectin), antigen or epitope sequence, and optionally a polypeptide sequence
IL147270A0 (en) 1999-07-02 2002-08-14 Genentech Inc Fusion peptides comprising a peptide ligand domain and a multimerization domain

Also Published As

Publication number Publication date
US20100098718A1 (en) 2010-04-22
US7541180B2 (en) 2009-06-02
US7994283B2 (en) 2011-08-09
EP1440156A2 (de) 2004-07-28
WO2002098456A2 (en) 2002-12-12
WO2002098456A3 (en) 2004-05-06
US20040147721A1 (en) 2004-07-29
EP1440156B1 (de) 2008-08-27
DE60228603D1 (de) 2008-10-09
GB0113798D0 (en) 2001-07-25

Similar Documents

Publication Publication Date Title
ATE406449T1 (de) Antigene und vektoren für impfung
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
EP1453850A4 (de) Egvii-endoglucanase und dafür codierende nukleinsäuren
CY1109664T1 (el) Πρωτεϊνες δεσμευσεως ιντερλευκινης-18, η παρασκευη και η χρηση τους
ATE461938T1 (de) Mit entzündlichen darmerkrankungen (ibd) assoziierte mikrobielle antigene und verfahren derer anwendung
CY1118037T1 (el) Αντισωματα εναντι του αβητα και h χρηση τους
WO2002080851A3 (en) Chimeric vaccines
DE60232577D1 (de) Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
SG153874A1 (en) Neutralizing epitope-based growth enhancing vaccine
EP1490094A4 (de) Antikörper-fusionsproteine: wirksame adjuvantien bei der proteinvakzination
IL157446A0 (en) Increased recovery of active proteins
BRPI0411854A (pt) veìculos protéicos para vacinas
DK1530637T3 (da) Carlsberg-subtilisin-proteiner med nedsat immunogenitet
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
DE60315827D1 (de) Verbesserte polysaccharid- und glykokonjugat-vakzine
ATE490785T1 (de) Parathormon-antikörper und damit zusammenhängende verfahren
ATE439441T1 (de) Veränderte, fluoreszierende proteine
DK1274853T3 (da) Materialer og fremgangsmåder, der angår immunreaktioner på fusionsproteiner
DE60025704D1 (de) Das goodpasture-antigen bindende protein
DK1499349T3 (da) Rekombinante hybrid-allergenkonstrukter med reduceret allergenitet, der bibeholder det naterulige allergens immunogenitet
WO2003031642A3 (en) lovE VARIANT REGULATOR MOLECULES
WO2004056316A3 (en) Vaccines against hiv-1 tat protein to generate neutralizing antibodies
WO2004087883A3 (en) lovE VARIANT REGULATOR MOLECULES
DK1328621T3 (da) 13245, en ny human proteinkinase af den myotoniske dystrofitype og anvendelser deraf

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1440156

Country of ref document: EP